Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH conjugate cancer vaccines

Vaccine

Volumn 18, Issue 7-8, 1999, Pages 597-603

  Kim, Soo Kie ^a   Ragupathi, Govindaswami ^a   Musselli, Cristina ^a   Choi, Sun Ju ^b   Park, Yoon Sun ^c   Livingston, Philip O ^a  

^a Lab of Devmtl Tumor Vaccinology   (United States)

^b Korea Basic Science Institute (KBSI)   (South Korea)

^c Catholic Kwandong University   (South Korea)

Author keywords

Adjuvant; Conjugate vaccine; GD3; IFN ; IL 4; KLH; MUC1

Indexed keywords

CANCER VACCINE; GAMMA INTERFERON; GANGLIOSIDE GD3; GANGLIOSIDE GD3 KEYHOLE LIMPET HEMOCYANIN CONJUGATE VACCINE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 4; KEYHOLE LIMPET HEMOCYANIN; MUC1 PEPTIDE; MUC1 PEPTIDE KEYHOLE LIMPET HEMOCYANIN CONJUGATE VACCINE; QS 21; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CANCER CELL DESTRUCTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG FORMULATION; FEMALE; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINE PRODUCTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, NEOPLASM; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; CA-15-3 ANTIGEN; CANCER VACCINES; CYTOKINES; FEMALE; GANGLIOSIDES; HEMOCYANIN; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; T-LYMPHOCYTES; VACCINES, CONJUGATE;

EID: 0010993390     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00316-3     Document Type: Article

References (20)

1. Livingston P.O., Zhang S., Lloyd K.O. Carbohydrate vaccines that induce antibodies against cancer. Part I. Rational. Cancer Immunol. Immunother. 45:1997;1-9.
2. Zhang H., Zhang S., Cheung N.K., Ragupathi G., Livingston P.O. Antibodies can eradicate cancer micrometastases. Cancer Res. 58:1998;2844-2849.
3. Livingston P.O., Wong G.Y.C., Adluri S., Tao Y., Padavan M., Parente R., Hanlon C., Helling F., Ritter G., Oettgen H.F., Old L.J. Improved survival in AJCC stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J. Clin. Oncol. 12:1994;1036-1044.
4. Jones P.C., Sze L.L., Liu P.Y., Morton D.L., Irie R.F. Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen. J. Natl. Cancer Inst. 66:1981;249-254.
5. Riethmuller G., Schneider-Gadicke E., Schlimok G., Schmiegel W., Raab R., Hoffken K., Gruber R., Pichlmaier H., Hirche H. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet. 343:1994;1177-1183.
6. Helling F., Shang Y., Calves M., Oettgen H.F., Livingston P.O. Increased immunogenicity of GD3 conjugate vaccines: comparision of various carrier proteins and selection of GD3-KLH for further testing. Cancer Res. 54:1994;197-203.
7. Helling F., Zhang A., Shang A., Adluri S., Calves M., Koganty R., Longenecker B.M., Oettgen H.F., Livingston P.O. GM2-KLH conjugate vaccine: Increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res. 55:1995;2783-2788.
8. Livingston P.O. Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccines. Immunol. Rev. 145:1995;145-166.
9. Livingston P.O., Ritter G., Calves M.J. Antibody response after immunization with the gangliosides GM1, GM2, GM3, GD2, and GD3 in the mouse. Cancer Immunol. Immnother. 29:1989;179.
10. Zar H.J. Rank correlation. Biostatistical analysis. 1974;243-246 Prentice-Hall Inc, Englewood Cliffs, NJ.
11. Livingston P.O., Koganty R., Longenecker B.M., Lloyd K.O., Calves M. Studies on the immunogenicity of synthetic and natural Thomsen-Friedenreich (TF) antigens in mice: Augmentation of the response by Quil A and SAF-m adjuvants and analysis of the specificity of the responses. Vaccine Res. 1:1992;99-109.
12. Zhang S., Walberg L.A., Helling F., Ragupathi G., Adluri S., Lloyd K.O., Livingston P.O. Augmenting the immunogenicity of synthetic MUC-1 vaccines in mice. Cancer Res. 55:1996;3364-3368.
13. Helling F., Zhang A., Shang A., Adluri S., Calves M., Koganty R., Longenecker B.M., Oettgen H.F., Livingston P.O. GM2-KLH conjugate vaccine: Increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res. 55:1995;2783-2788.
14. Livingston P.O., Adluri S., Zhang S., Chapman P.B., Raychaudhuri S., Merritt J.A. Impact of immunological adjuvants and administration route on HAMA response after immunization with murine monoclonal antibody MELIMMUNE-1 in melanoma patients. Vaccine Res. 4:1995;87-94.
15. Kensil C.R., Patel U., Lennick M., Marciani D. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria molina cortex. J. Immunol. 146:1991;431-437.
16. Ribi E., Amano K., Cantrell J., Schwartzman S., Parker R., Takayama K. Preparation and antitumor activity of nontoxic lipid A. Cancer Immunol. Immunother. 12:1982;91-96.
17. Hunter R., Bennett B. The adjuvant activity of nonionic block polymer surfactants. II. Antibody formation and inflammation related to the structure of triblock and octablock copolymers. J. Immunol. 133:1984;3167-3174.
18. Todd C.W., Pozzi L.A., Guarnaccia J.R., Balusubramnian M., Henk W.G., Younger L.E., Newman M.J. Development of an adjuvant-active nonionic block copolymer for use in oil-free subunit vaccine formulations. Vaccine. 15:1997;564-570.
19. Weiner G.J., Liu H-M., Wooldridge J.E., Dahle C.E., Krieg A. Immunostimulatory oligonucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc. Natl. Acad. Sci. 94:1997;10833-10837.
20. Lo K.M., Sudo Y., Chen J., Li Y., Lan Y., Kong S.M., Chen L., An Q., Gillies S.D. High level expression and secretion of Fc-X fusion proteins in mammalian cells. Protein Eng. 11:(6):1998;495-500.